Tiger Brokers

NeoGenomics on 'More Solid Footing' With Strong Revenue Growth, Needham Says

MT Newswires Live
13 hours ago

NeoGenomics (NEO) is on "more solid footing" even after another change in the chief executive officer role, Needham said in a Tuesday note, citing revenue growth in next-generation sequencing and reimbursement wins for RaDaR MRD.

Current Chief Operating Officer Warren Stone is set to become the company's fifth CEO in the past six years, as he succeeds current CEO Tony Zook on Jan. 4, Needham analysts said.

Further, the analysts said they were "encouraged" by the company's above-consensus Q3 revenue guidance of about $209 million, including year-over-year next-generation sequencing revenue growth of around 28%.

Needham reiterated the company's stock at buy and raised the price target to $22 from $19.

Price: 16.70, Change: -2.43, Percent Change: -12.71

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10